Pharmacological characterization of a novel nonpeptide antagonist radioligand, (±)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 1, 2003, Pages 57-69

  Zhang, Ge ^a,b   Huang, Ning ^a   Li, Yu Wen ^a   Qi, Xiaoping ^a   Marshall, Anne P ^a   Yan, Xiao Xin ^a   Hill, Geraldine ^a   Rominger, Cynthia ^a   Prakash, Shimoga R ^a   Bakthavatchalam, Rajagopal ^a   Rominger, David H ^a   Gilligan, Paul J ^a   Zaczek, Robert ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR; N (2 METHYL 4 METHOXYPHENYL) 1 [1 (METHOXYMETHYL)PROPYL] 6 METHYL 1H 1,2,3 TRIAZOLO[4,5 C]PYRIDIN 4 AMINE; RADIOLIGAND; SN 003; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG EFFECT; HORMONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; TISSUE DISTRIBUTION;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BINDING SITES; CELL MEMBRANE; CELLS, CULTURED; CYCLIC AMP; HUMANS; MALE; PYRIDINES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TRIAZOLES; TRITIUM;

EID: 0037379954     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.046128     Document Type: Article

References (40)

1. Aguilera G, Millan MA, Hauger RL, and Catt KJ (1987) Corticotropin-releasing factor receptors: distribution and regulation in brain, pituitary, and peripheral tissues. Ann NY Acad Sci 512:48-66.
2. 1 receptors in amygdala. J Neurosci 22:2926-2935.
3. Bakthavatchalam R, Arvanitis AG, Beck JP, Cain GA, Chorvat RJ, Gilligan PJ, and Olson RE (1997) Arglamino fused pyridines and pyrimidines. International Publication Number WO 97/35539.
4. Beyermann M, Fechner K, Furkert J, Krause E, and Bienert M (1996) A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor. J Med Chem 39:3324-3330.
5. Bymaster FP and Falcone JF (2000) Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. Eur J Pharmacol 390:245-248.
6. Dautzenberg FM and Hauger RL (2002) The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23:71-77.
7. Davis M (1992) The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends Pharmacol Sci 13:35-41.
8. De Souza EB (1987) Corticotropin-releasing factor receptors in the rat central nervous system: Characterization and regional distribution. J Neurosci 7:88-100.
9. De Souza EB and Grigoriadis DE (1998) Corticotropin-releasing factor. Physiology, pharmacology and role in central nervous system and immune disorders, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 505-517, Raven Press, New York.
10. De Souza EB, Insel TR, Perrin MH, Rivier J, Vale WW, and Kuhar MJ (1985) Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci 5:3189-3203.
11. Gilligan PJ, Robertson DW, and Zaczek R (2000) Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J Med Chem 43:1641-1660.
12. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, and Soubrié P (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl- 1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor1 receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333-345.
13. Grigoriadis DE and De Souza EB (1988) The brain corticotropin-releasing factor (CRF) receptor is of lower apparent molecular weight than the CRF receptor in anterior pituitary: evidence from chemical cross-linking studies. J Biol Chem 263:10927-10931.
14. Grigoriadis DE and De Souza EB (1989) Heterogeneity between brain and pituitary corticotropin-releasing factor receptors is due to differential glycosylation. Endocrinology 125:1877-1888.
15. Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C, Darre V, Marcy C, Rouby PE, Simiand J, et al. (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1 (3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factorl receptor antagonist. I. Biochemical and pharmacological characterization. J Pharmacol Exp Ther 301:322-332.
16. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, et al. (2000) Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97:6079-6084.
17. Hauger RL, Dautzenberg FM, Flaccus A, Liepold T, and Spiess J (1997) Regulation of corticotropin-releasing factor receptor function in human Y-79 retinoblastoma cells: rapid and reversible homologous desensitization but prolonged recovery. J Neurochem 68:2308-2316.
18. 1 receptor antagonist. J Med Chem 43:449-456.
19. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, and Grigoriadis DE (2002) Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27:194-202.
20. Horlick RA, Sperle K, Breth LA, Reid CC, Shen ES, Robbins AK, Cooke GM, and Largent BL (1997) Rapid generation of stable cell lines expressing corticotropin-releasing hormone receptor for drug discovery. Protein Expr Purif 9:301-308.
21. Keck ME and Holsboer F (2001) Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides 22:835-844.
22. Keller C, Bruelisauer A, Lemaire M, and Enz A (2002) Brain pharmacokinetics of a non-peptidic corticotropin-releasing factor antagonist. Drug MetabDispos 30:173-176.
23. 2/receptor. Mol Endocrinol 12:1077-1085.
24. Lewis K, Li C, Perrin MH, Blount A, Kunitake KS, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, et al. (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) with high affinity for the CRF2 receptors. Proc Natl Acad Sci USA 98:7570-7575.
25. 3H]-SN003, a small molecule corticotropin releasing factor receptor type-1 antagonist, in the rat brain. Soc Neurosci Abstr 27:414.1.
26. Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, and Maki RA (1997) Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol 11:2048-2053.
27. Maciag CM, Gersham D, Gilligan PJ, He L, Dowling K, Ko T, Levine S, and Smith MA (2002) Effects of a non-peptide CRF antagonist (DMP696) on the behavioral and endocrine sequelae of maternal separation. Neuropsychopharmacology 26: 574-582.
28. 1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr Pharm Des 5:289-315.
29. 1 receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats. Psychopharmacology 165:86-92.
30. Owens MJ and Nemeroff (1991) Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43:425-473.
31. Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K, Sawchenko PE, and Vale W (1994) Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci USA 9:8777-8781.
32. 2 binding sites in adult rat brain. Neuropyschopharmacology 17:308-316.
33. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier W, Vale W, et al. (2001) Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98:2843-2848.
34. 2 receptors: membrane homogenate and autoradiographic studies. J Pharmacol Exp Ther 286: 459-468.
35. Rosenkilde MM, Cahir M, Gether U, Hjorth SA, and Schwartz TW (1994) Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. J Biol Chem 269:28160-28164.
36. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, et al. (1996) CP-154, 526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 93:10477-10482.
37. Tian X, Hsin LW, Webster EL, Contoreggi C, Chrousos GP, Gold PW, Habib K, Ayala A, Eckelman WC, Jacobson AE, et al. (2001) The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor typel. Bioorg Med Chem Lett 11:331-333.
38. Vale W, Grant G, Amoss M, Blackwell R, and Guillemin R (1972) Culture of enzymatically dispersed anterior pituitary cells: functional validation of a method. Endocrinology 91:562-572.
39. Vale W, Spiess J, Rivier C, and Rivier J (1981) Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science (Wash DC) 213:1394-1397.
40. 1) receptors. Soc Neurosci Abstr 27: 179.17.